ArticleNPJ precision oncology2025
Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A positive feedback loop between TKT and c-Myc drives TACE resistance in hepatocellular carcinoma.Cell death discovery · 2026Article
- A novel signature of palmitoylation for predicting prognosis and therapeutic response of hepatocellular carcinoma.Discover oncology · 2026Article
- Multicenter Validation of a RAR-Based Nomogram for Predicting Postoperative Progression in HBV-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Survival following transarterial chemoembolisation (TACE) for hepatocellular cancer (HCC) is variable. We explored targeted sequencing of circulating tumour DNA (ctDNA) as a prognostic biomarker. Plasma samples (n = 97) were collected at baseline and following TACE. Targeted, ultra-deep sequencing was conducted on 18 somatic mutations related to the molecular pathogenesis of HCC. Median progression-free survival and overall survival were 11.6 months (95% CI: 5.83-21.2) and 34 months (95% CI: 22.35-45.60), respectively. CTNNB1 and ARID1A were the most frequently mutated genes, present in 25% of baseline circulating samples, followed by SF3B1 (20%) and TERT (18%). The presence of mutations in CTNNB1, TP53 ARID1A, and KEAP1 predicted for poor OS on univariable analysis. Findings suggest that ctDNA profiling of known genetic drivers of HCC may serve as a valuable prognostic biomarker prior to TACE and may assist with the stratification of patients following further evaluation in larger studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.